|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 3, May-June 2017
BENEFITS OF THE NOVEL USE OF A COMPOUNDED ORAL SUSPENSION IN CHEMOTHERAPY AND RADIOTHERAPY INDUCED MUCOSITIS
MAÑES SEVILLA MIREYA, GONZÁLEZ HABA EVA, MARZAL ALFARO MARÍA BELÉN, COLLADO BORREL ROBERTO, PERNIA SAGRARIO, HERRANZ ALONSO ANA, SANJURJO SÁEZ MARÍA
Purpose: To identify the onco-hematological patients who can be benefit of the compounded oral suspension for mucositis (COSM), developed by the Pharmacy Department, and describe its using profile in hospitalized patient.
Method: This observational, descriptive, retrospective, cohort study included onco-hematological patients who presented mucositis and were treated with the COSM. Electronic prescriptions were used to collect the data: patients’ characteristics, clinical variables; reason for the appearance; drugs involved; therapy of the COSM; tolerance; additional topical treatment; analgesic and anti-microbial treatment; nutritional support and date of mucositis resolution.
Results: Seventy patients were included. The most common diagnoses were: acute myeloid leukemia and head and neck cancer. The severity of mucositis was mainly grade I. Mucositis was related to chemotherapy treatment in 73% of the patients. Radiotherapy treatment caused mucositis in 27% of the patients. All the patients had a good tolerance to the suspension. Sixty-three patients received analgesic treatment during the hospitalization and twenty-three patients required morphine. Seven patients required parenteral nutrition support during hospital admission, however it was discontinued, in all patients, before the hospital discharge. Also twenty-five patients needed antimicrobials for the prevention of fungal infections. In 50% of the patients mucositis was resolved by the 8th day (IQR: 14-3).
Conclusion: Our study demonstrated that the COSM is widely and effectively used in chemotherapy and radiotherapy-treated patients. Despite establishing a systemic treatment, the suspension has been maintained to sooth pain. In addition, our study suggests that only 10% of patients needed parenteral nutrition support. Our mouthwash could have minimized the required nutritional support.
BENEFIT – CARE ONCOLOGY – COMPOUNDED ORAL SUSPENSION – MUCOSITIS